Welcome to our dedicated page for Ocean Biomedical news (Ticker: OCEA), a resource for investors and traders seeking the latest updates and insights on Ocean Biomedical stock.
Ocean Biomedical Inc. (OCEA) is a biopharmaceutical innovator developing targeted therapies for oncology, fibrosis, and infectious diseases. This page provides investors and researchers with essential updates on clinical advancements, strategic partnerships, and regulatory milestones.
Access the latest press releases detailing OCEA's progress in immune checkpoint modulation and small molecule therapeutics. Stay informed about developments in bispecific antibody candidates targeting PD-1/CTLA-4 pathways and Chit1-focused fibrosis treatments.
Key updates include clinical trial progress, research collaborations, and scientific publications. Bookmark this page for real-time insights into OCEA's work addressing unmet medical needs through antibody engineering and molecular discovery.
Ocean Biomedical (NASDAQ: OCEA) announced a strategic expansion beyond its core biopharmaceutical business into power infrastructure development and cryptocurrency investments. The expansion, announced on April 22, 2025, aims to generate stable cash flow to support the company's primary biopharma operations.
The company plans to develop and operate data center-grade power infrastructure and implement a digital treasury strategy focusing on Bitcoin and Solana cryptocurrencies. Chairman Chirinjeev Kathuria emphasized that while maintaining commitment to their scientific pipeline, these new ventures will help build recurring revenue streams to fund biomedical innovations.
The strategic diversification leverages the company's existing leadership expertise and targets high-growth sectors driven by AI and digital infrastructure demand. Ocean Biomedical will provide further details about power project specifications and cryptocurrency investment framework in upcoming months.
Ocean Biomedical (NASDAQ: OCEA) has received a patent grant from the China National Intellectual Property Administration (CNIPA) for its bispecific antibodies targeting CHI3L1 and PD1, designed to enhance tumor cell destruction. The patent strengthens the company's intellectual property portfolio in one of the world's largest pharmaceutical markets.
The technology represents a potential breakthrough in cancer immunotherapy by simultaneously targeting CHI3L1, a key regulator of immune suppression, and PD1, an established immune checkpoint. This dual-targeting approach aims to overcome current limitations in cancer treatment by blocking two key pathways tumors use to suppress immune response, potentially leading to more effective and durable patient outcomes.
This grant extends Ocean Biomedical's patent protection beyond its existing coverage in the United States and Europe, supporting its global expansion strategy in cancer immunotherapy development.
Ocean Biomedical (NASDAQ: OCEA) has announced breakthrough research findings showing their cancer immunotherapy candidates effectively interact with tyrosine kinase inhibitors (TKI) in treating non-small cell lung cancer (NSCLC). The research, published in Translational Oncology, demonstrates the therapy's ability to restore treatment sensitivity in osimertinib-resistant cases and suppress tumor growth when combined with TKI therapies.
The company's proprietary antibody suppresses CHi3L1 activity, leading to significant tumor reduction in preclinical models. Ocean Biomedical has also developed bispecific antibodies combining anti-CHI3L1 with anti-PD-1 or anti-CTLA4, showing efficacy in NSCLC, melanoma, and glioblastoma models.
The company plans to initiate preclinical studies and engage with the FDA this year for first-in-human trials. This development aligns with industry trends toward bispecific antibodies, highlighted by Merck's recent $588 million acquisition of LaNova's LM-299.
Ocean Biomedical (NASDAQ: OCEA) has announced significant advances in its malaria vaccine research program. The company's Scientific Co-founder, Dr. Jonathan Kurtis, has secured additional $3.5 million NIH funding and may benefit from new FDA guidance on lipid-encapsulated vaccines that could expedite development.
The research team has identified a unique protein called GARP on malaria-infected red blood cells, discovered through studies of children who naturally developed resistance to severe malaria. With a $4.6 million non-governmental Foundation grant, the team is currently testing three vaccine candidates in non-human primates.
The company aims to utilize lipid-encapsulated mRNA technology for vaccine delivery and plans to potentially initiate human trials by Q4 2025. The research focuses on blocking the malaria parasite's ability to enter and exit red blood cells, targeting a disease that claims over 500,000 children's lives annually in sub-Saharan Africa.
Ocean Biomedical (NASDAQ: OCEA) received a notice from Nasdaq on November 18, 2024, regarding non-compliance with listing rules due to failure to file its Q3 2024 Form 10-Q. This follows previous delays in filing its 2023 10-K and Q1/Q2 2024 10-Qs. While there's no immediate effect on stock listing, the company's securities are subject to delisting. A Nasdaq Hearings Panel will review the case on December 16, 2024. The company plans to file all delinquent reports as soon as possible.
Ocean Biomedical (NASDAQ: OCEA) announced receipt of a Nasdaq Staff Determination Letter on October 16, 2024. The letter states that the company failed to comply with Nasdaq's filing requirements as per Listing Rule 5250(c)(1). Specifically, Ocean Biomedical did not file its Form 10-K for the year ended December 31, 2024, and Forms 10-Q for the periods ended March 31, 2024, and June 30, 2024. Despite being granted an exception until October 14, 2024, to regain compliance, the company did not meet the terms. Ocean Biomedical will appeal this determination to a Hearings Panel as per Nasdaq Listing Rule 5800 Series procedures.
Ocean Biomedical (NASDAQ:OCEA) announced new research published in the Journal of Immunology by Scientific Co-founder Dr. Jack A. Elias and colleagues. The study expands understanding of how CHI3L1 inhibits the body's natural immune responses to lung cancers and related diseases like COPD. It demonstrates for the first time how CHI3L1 inhibits macrophage phagocytosis by stimulating two key phagocytosis checkpoint pathways.
The research suggests that CHI3L1-targeted therapeutics are promising interventions in cancer, COPD, and other disorders. Ocean Biomedical's monoclonal antibody is part of a unique oncology platform working to activate natural cancer immune responses by suppressing Chi3L1, with potential for broad application. The company has been granted patent allowance for multiple cancer types, including Prostate, Colon, Rectal, Ovarian, Kidney, Breast, Glioblastoma, Melanoma, and Lung Cancer.
Ocean Biomedical (NASDAQ:OCEA) announced a key U.S. patent issued for Dr. Jonathan Kurtis' groundbreaking malaria therapeutic antibody discovery targeting PfGARP. This patent expands protection for novel approaches to malaria prevention and treatment, including:
1. A powerful vaccine candidate for long-term prevention
2. A therapeutic antibody for short-term prevention
3. A small molecule drug to treat severe malaria
The patent adds to Ocean Biomedical's portfolio of over 60 patents developed through $125M in grants. This novel approach causes parasite death at a key stage in the malarial cycle, addressing growing resistance to current Artemisinin-based drugs. The company aims to develop new treatment options to combat malaria, which killed approximately 627,000 individuals in 2022.
Ocean Biomedical (NASDAQ: OCEA) has received a notice from Nasdaq due to its failure to file the Q2 2024 Form 10-Q on time. This non-compliance with Nasdaq Listing Rule 5250(c)(1) stems from previously disclosed issues related to the company's 2023 10-K filing. While there's no immediate impact on OCEA's stock listing or trading, the company must submit a compliance plan by September 3, 2024, and file the delinquent reports by October 14, 2024. These include the Q2 2024 10-Q, Q1 2024 10-Q, and 2023 10-K. Ocean Biomedical intends to file these reports as soon as possible. The situation highlights potential risks for investors, as continued delays could affect the stock's listing status.
Ocean Biomedical (NASDAQ: OCEA) congratulated its JV partner Virion Therapeutics on presenting successful Phase 1b data for VRON-0200, a novel immunotherapy aiming for an HBV functional cure, at EASL 2024 Congress.
The data showcased that VRON-0200, using glycoprotein D as a checkpoint modifier, is safe, well-tolerated, and immunogenic for chronic HBV patients after a single intramuscular injection. This treatment could stimulate T cell responses even in patients with little to no prior HBV immunity.
This development could support Virion's other pipeline programs, such as VRON-0300 for advanced tumors. The global chronic HBV treatment market is expected to reach $6.5 billion by 2032, reflecting the high demand for new treatments.